Urinary incontinence in dogs is a distressing condition that affects both the patient's quality of life and the owner's household environment. By far the most common medical cause of incontinence in adult dogs is urethral sphincter mechanism incompetence (USMI), colloquially known as spay incontinence or weak bladder sphincter (a condition linked to spaying — see our guide to when to spay or neuter your dog for the procedure-level context). For decades, the primary pharmacological defense against this condition in the United States has been phenylpropanolamine hydrochloride (PPA)—most widely recognized by the brand name Proin, and its once-daily formulation, Proin ER.

Approved by the FDA under NADA 141-324 (for the immediate-release chewable tablets) and later under NADA 141-517 (for the extended-release once-daily tablets, approved on March 29, 2019, and sponsored by Pegasus Laboratories), Proin is indicated specifically for the control of urinary incontinence due to urethral sphincter hypotonus in dogs.

While Proin is highly effective at restoring continence, it is a sympathomimetic drug with systemic cardiovascular effects. Furthermore, the history of PPA is intertwined with its removal from the human over-the-counter (OTC) pharmaceutical market in 2000 due to concerns over hemorrhagic stroke.

This comprehensive, data-anchored guide examines the clinical pharmacology of phenylpropanolamine, reviews its efficacy and study history, quantifies its real-world safety profile through 3,594 deduplicated FDA adverse-event reports, details the critical blood-pressure cautions, and provides a structured clinical decision tree (escalation ladder) for cases where Proin fails or causes adverse effects.

---

What is Phenylpropanolamine (Proin) and How Does it Work?

Phenylpropanolamine is a synthetic sympathomimetic amine. It is structurally and pharmacologically related to endogenous catecholamines (such as epinephrine and norepinephrine) as well as other sympathomimetics like ephedrine and pseudoephedrine.

The Mechanism of Action: Alpha-Adrenergic Stimulation

To control urinary incontinence, PPA acts directly on the autonomic nervous system. The bladder and urethra are innervated by both sympathetic and parasympathetic nerve fibers:

• Detrusor Muscle (Bladder Wall): Primarily controlled by beta-adrenergic receptors (which promote relaxation to allow filling) and muscarinic cholinergic receptors (which promote contraction to allow voiding).
• Internal Urethral Sphincter: Innervated heavily by sympathetic fibers acting on alpha-1 (α-1) adrenergic receptors. When stimulated, these receptors cause the smooth muscle of the urethral sphincter to contract, increasing urethral resistance and preventing the passive leakage of urine.

In dogs with USMI, the tone of this internal sphincter is abnormally low, allowing urine to leak, especially when the dog is resting, sleeping, or recumbent (as abdominal pressure rises relative to urethral pressure).

Phenylpropanolamine acts as a direct agonist at α-1 adrenergic receptors located in the bladder neck and internal urethral sphincter. By binding to these receptors, PPA stimulates the smooth muscle fibers to contract, thereby increasing urethral closure pressure. PPA also exhibits indirect sympathomimetic effects by stimulating the release of endogenous norepinephrine from presynaptic nerve terminals, further reinforcing sphincter tone. It does not affect the voluntary skeletal muscle of the external urethral sphincter, nor does it affect the bladder detrusor muscle directly.

The Dosing Paradigm: Proin vs. Proin ER

Proin is available in two distinct formulations, which have different dosing shapes and safety rules:

1. Proin Chewable Tablets (Immediate-Release): Approved in 2011, these are administered at a labeled dosage of 2 mg/kg (0.9 mg/lb) of body weight twice daily (every 12 hours). The dose is rounded to the nearest half-tablet. Because of PPA's short half-life in dogs (approximately 3 to 4 hours), twice-daily dosing is required to maintain therapeutic blood levels and prevent breakthrough leaking.
2. Proin ER (Extended-Release Tablets): Approved in 2019, Proin ER uses a proprietary matrix that slowly releases PPA over 24 hours, allowing for once-daily dosing. The labeled dosage is 2 to 4 mg/kg of body weight once daily, administered with food.

[!IMPORTANT] Proin ER Safety Cautions

• Do Not Split or Crush: Proin ER tablets rely on an intact physical matrix to release the drug slowly. If a tablet is split, crushed, or chewed, the entire 24-hour dose of PPA is released immediately (known as "dose dumping"), which can cause dangerous acute hypertension.
• Not for Small Dogs: Proin ER is not labeled for use in dogs weighing less than 10 pounds (4.5 kg), as the minimum tablet strength (18 mg) would result in over-dosing.
• Administer with Food: Clinical studies demonstrate that administering Proin ER with food slows absorption and reduces the peak blood concentration (Cmax), smoothing the cardiovascular side-effect profile.

---

Efficacy and Clinical Study History

The approval of Proin and Proin ER was supported by rigorous target-animal safety and field efficacy studies.

The Proin ER Field Study Detail

The FDA Freedom of Information (FOI) summary for NADA 141-517 details the multi-center field efficacy study that led to the approval of the once-daily formulation.

The study enrolled 119 client-owned dogs diagnosed with urinary incontinence due to urethral sphincter hypotonus. The study population reflected the demographic reality of USMI:

• Gender: 113 spayed females and 6 neutered males. (USMI is highly prevalent in spayed females due to the lack of estrogen, which plays a synergistic role in maintaining alpha-adrenergic receptor sensitivity in the urethra).
• Most Common Purebred Breeds: The study population was dominated by large-breed dogs, which are statistically predisposed to USMI:
  • Labrador Retriever: 14 dogs
  • Doberman Pinscher: 11 dogs
  • German Shepherd: 8 dogs

Each dog was first confirmed as controlled on twice-daily immediate-release Proin during a baseline period, then transitioned to once-daily Proin ER while owners kept a daily diary of incontinence episodes. Effectiveness was judged by comparing accidents during the fourth week on Proin ER against the baseline week on the chewable formulation. Of the 104 dogs that completed the study, the large majority stayed dry or had fewer accidents on the once-daily formulation, demonstrating that switching from immediate-release PPA (twice daily) to extended-release PPA (once daily) maintained good control of urinary incontinence. The study also recorded a baseline rate of sympathomimetic side effects, including transient increases in heart rate and systemic blood pressure.

---

The Human PPA Regulatory History: Why the Ban?

A common source of anxiety for dog owners researching Proin is the discovery that phenylpropanolamine was "banned" or removed from the human pharmaceutical market.

The Yale Hemorrhagic Stroke Project

In the 1980s and 1990s, PPA was widely used in human medicine as a nasal decongestant in over-the-counter cold remedies and as an active ingredient in OTC appetite suppressants (diet pills). Because PPA is a sympathomimetic, concerns arose that it could cause acute spikes in blood pressure, leading to cerebrovascular accidents (strokes).

To investigate this, the Yale Hemorrhagic Stroke Project (HSP) was launched. The case-control study, published in 2000, evaluated men and women aged 18 to 49 who had suffered a hemorrhagic stroke. The results showed a statistically significant increase in the risk of hemorrhagic stroke among women who used PPA as an appetite suppressant, or who had recently taken PPA-containing cold remedies.

Following this study, on November 6, 2000, the FDA issued a public health advisory requesting that drug manufacturers voluntarily stop marketing products containing PPA. The FDA estimated that PPA was responsible for 200 to 500 hemorrhagic strokes per year in young adults in the United States. In 2005, the FDA finalized this action by publishing a tentative final monograph that removed PPA from the list of safe and effective OTC human drug ingredients.

Why Veterinary Proin Remained Approved

If PPA is dangerous enough to be removed from human shelves, why is it still prescribed to dogs? The FDA CVM evaluated this risk-benefit ratio and determined that PPA should remain available for veterinary use under prescription-only status for several reasons:

1. Distinct Indication and Patient Impact: In humans, PPA was used for self-limiting conditions (nasal congestion) or lifestyle management (weight loss), where the tolerance for serious risks like stroke is virtually zero. In dogs, USMI is a chronic, progressive condition that causes severe dermatitis, recurrent urinary tract infections (UTIs), and often leads to euthanasia or abandonment due to the inability to keep the dog indoors. The clinical benefit is therefore much higher.
2. Physiological Differences: Dogs have a significantly lower susceptibility to PPA-induced hemorrhagic strokes than humans. Canine blood vessels are structurally robust, and the primary manifestation of sympathomimetic toxicity in dogs is systemic hypertension, tachycardia, and behavioral changes rather than acute intracranial hemorrhage.
3. Controlled Prescription Access: While human OTC PPA was used without medical supervision, veterinary Proin is a prescription-only medication that requires a veterinarian-client-patient relationship, baseline screening, and regular blood pressure monitoring.

---

What Do 3,594 FDA Adverse-Event Reports Show?

To establish the real-world safety profile of phenylpropanolamine in dogs, we performed a query and deduplication of the FDA/CVM openFDA animal adverse-event database using the July 5, 2026 snapshot.

Our analysis identified 3,594 unique adverse-event reports naming phenylpropanolamine. Consistent with the primary clinical indication, the database is heavily dominated by canine patients:

• Dogs: 3,279 reports (91.2% of the dataset)
• Cats: 2 reports (PPA is not used in cats, as feline USMI is extremely rare)
• Humans: 15 reports (reflecting a small number of accidental exposures, such as a pet owner accidentally ingesting the dog's beef-flavored chewable tablet)
• Other or Unspecified Species: 298 reports — almost all (~294) are reports in which the species field was not recorded

The outcome distribution across the 3,594 reports reflects the generally manageable nature of PPA side effects, though serious outcomes are recorded:

• Recovered/Normal: 1,533 reports
• Outcome Unknown/Not Provided: 1,000 reports
• Ongoing (still being treated or resolving at the time of the report): 429 reports
• Euthanized: 156 reports
• Died: 107 reports
• Recovered with Sequelae (lasting effect after recovery): 45 reports

Because a single report can list more than one outcome—and many list none—these categories overlap and do not sum to the total report count. The combined death and euthanasia reports (107 Died plus 156 Euthanized = 263, about 7.3% of the dataset) are significantly lower than those seen with NSAIDs like carprofen (~17%). Many of these deaths occurred in dogs with pre-existing, advanced cardiovascular or renal disease, or after massive accidental ingestions of entire bottles of chewable tablets.

The Reaction Spectrum: The "Lack of Efficacy" and Sympathomimetic Signals

A breakdown of the specific clinical signs reported for phenylpropanolamine reveals a highly characteristic pattern:

Clinical Reaction	FDA Report Count	Clinical Interpretation / Category
Vomiting	496	Gastrointestinal
Lack of Efficacy	452	Therapeutic Failure
Lethargy	450	Systemic
Emesis	427	Gastrointestinal
Accidental Ingestion / Exposure	317	Toxicology (Overdose)
Panting	311	Sympathomimetic / Agitation
Diarrhea	297	Gastrointestinal
Agitation / Restlessness	250	Sympathomimetic (CNS)
Overdose	233	Toxicology (Dosing error)
Anorexia	228	Gastrointestinal / Systemic
Underdose	191	Therapeutic (Dosing error)
Hypertension (High Blood Pressure)	144	Cardiovascular

Note: "Vomiting" and "Emesis" are recorded as separate coded reaction terms in the FDA dataset and overlap conceptually; both are gastrointestinal signs. A smaller number of reports also list tachycardia (rapid heart rate), another direct sympathomimetic effect.

Two key findings emerge from this data:

1. The "Lack of Efficacy" Signal (452 reports): Lack of efficacy is the second most common report in the database. This shows that PPA is not universally effective. In many dogs, the urethral sphincter does not respond sufficiently to α-1 stimulation, or the dog develops tolerance (tachyphylaxis) over time, requiring dose escalation or a switch to alternative therapies.
2. The Sympathomimetic Signal: Clinical signs like panting (311), agitation (250), and hypertension (144) are direct manifestations of PPA's action as a sympathetic nervous system stimulant. This pattern represents the primary safety concern for the drug.

---

Cardiovascular Risks and Blood Pressure Cautions

Because phenylpropanolamine stimulates α-1 adrenergic receptors, its effects are not confined to the urethra. It causes systemic vasoconstriction throughout the body, which increases systemic vascular resistance and raises blood pressure.

The Sympathomimetic Reaction Pattern

In a dog taking Proin, sympathetic stimulation can manifest as:

• Hypertension: Elevated blood pressure. In healthy dogs, this increase is often mild and transient, but in sensitive dogs or those with subclinical disease, it can progress to systemic hypertension (systolic blood pressure >160–180 mmHg).
• Reflex Bradycardia: When PPA causes a sudden rise in blood pressure, the body's baroreceptors trigger a reflex decrease in heart rate to compensate. Consequently, some dogs on Proin exhibit a slower-than-normal heart rate.
• Tachycardia and Arrhythmias: If PPA's direct stimulatory effect on cardiac beta-receptors dominates, it can cause a rapid heart rate or prompt ectopic heartbeats.
• CNS Agitation: Restlessness, pacing, panting, irritability, or difficulty sleeping. The dog may act "hyper" or display increased anxiety.

Contraindications and High-Risk Patients

Due to these cardiovascular effects, the Proin label warns that the drug should be used with extreme caution, or avoided entirely, in dogs with:

• Pre-existing Hypertension: High blood pressure of any cause.
• Cardiovascular Disease: Heart murmurs, congestive heart failure, or arrhythmias. PPA increases the workload on the heart muscle.
• Chronic Kidney Disease: Hypertension can accelerate renal damage by causing glomerular sclerosis.
• Endocrine Diseases:
  • Diabetes Mellitus: Sympathomimetics can stimulate glycogenolysis and interfere with insulin regulation.
  • Hyperadrenocorticism (Cushing's): Dogs with Cushing's are already predisposed to systemic hypertension.
• Glaucoma: Alpha-adrenergic stimulation can increase intraocular pressure.

Furthermore, safety has not been established in breeding, pregnant, or nursing dogs. PPA can cause uterine contractions and vasoconstriction of placental blood vessels, leading to fetal death or developmental defects.

Blood-Pressure Monitoring Protocol

To ensure patient safety, a standard monitoring cadence should be followed:

1. Baseline Measurement: Measure the dog's blood pressure before starting Proin. If the systolic blood pressure is >150 mmHg, the underlying cause must be investigated, and PPA should be avoided.
2. The 2-Week Re-check: Re-check blood pressure 14 days after starting therapy or after any dose increase. The measurement should ideally be taken 2 to 4 hours post-dose, which corresponds to the peak blood concentration (Cmax) of PPA.
3. Routine Monitoring: For dogs on long-term therapy, blood pressure should be measured every 6 months alongside routine labwork.

---

What to Do If Proin Fails or Causes Side Effects: The Escalation Ladder

If a dog on Proin continues to leak urine (lack of efficacy) or develops unacceptable side effects (such as severe restlessness, panting, or hypertension), the clinician should follow a structured clinical pathway.

Clinical Decision Workflow (The Escalation Ladder)

1. Rule Out Secondary Causes: Perform a urinalysis and urine culture.
   • If a UTI or bladder stones are present: Treat the infection/stones first, then re-evaluate.
   • If there is no infection/stone: Proceed to clinical analysis of the issue.
2. Determine the Issue (Side Effects vs. Lack of Efficacy):
   • If the issue is Side Effects (e.g., hypertension, panting, anxiety): Reduce the Proin dose or switch to an estrogen-based alternative (DES or estriol/Incurin).
   • If the issue is Lack of Efficacy (continued leaking): Increase the Proin dose up to the maximum labeled limit (2 mg/kg twice daily).
3. Refractory Incontinence (If leaking persists at max dose):
   • Synergistic Medical Therapy: Add a low dose of estrogen (DES or Incurin) to a low/moderate dose of Proin (combining mechanisms).
   • Interventional/Surgical Options: If combination therapy fails, evaluate the dog for advanced options like urethral bulking (collagen injections) or an artificial urethral sphincter (AUS) implant.

---

Step 1: Rule Out Secondary Causes

Before assuming the drug has failed, the veterinarian must perform a urinalysis and urine culture. Secondary urinary tract infections (UTIs), bladder stones (urolithiasis), or subclinical kidney disease can cause bladder inflammation and urinary urgency, mimicking USMI. If a UTI is present, it must be treated with appropriate antibiotics before adjusting incontinence medications.

Step 2: Adjust Dosing and Formulation

• For Lack of Efficacy: If the dog is on immediate-release chewable tablets and is still leaking, the dose can be titrated upward under veterinary supervision, up to the maximum labeled limit of 2 mg/kg twice daily. Alternatively, switching to once-daily Proin ER can sometimes smooth blood levels and resolve breakthrough leaking.
• For Side Effects: If the dog is anxious or panting, reducing the dose to the lowest effective level (often 1 mg/kg twice daily) can resolve the signs while maintaining continence.

Step 3: Switch or Combine with Estrogen-Based Therapies

If PPA cannot be tolerated due to cardiovascular risks, or if it is ineffective at maximum doses, estrogen-based therapies represent the primary alternative:

• Diethylstilbestrol (DES): DES is a synthetic estrogen that was historically the standard treatment for spay incontinence. Because of human safety concerns (linked to cervical cancer in women exposed in utero), DES is no longer commercially manufactured but is readily available through veterinary compounding pharmacies. Estrogen works by increasing the density and sensitivity of alpha-adrenergic receptors in the urethral smooth muscle. Thus, estrogen and PPA have a synergistic effect.
• Estriol (Incurin): Estriol is a short-acting, natural estrogen that is FDA-approved for spay incontinence in dogs. Unlike DES, which is compounded, Incurin is a manufactured tablet. It is dosed once daily and titrated to the lowest effective dose.
• Combination Therapy: For refractory cases, combining a low dose of Proin with a low dose of DES or Incurin can achieve continence while avoiding the high-dose side effects of either drug.

Note on Estrogen Risks: Estrogen therapies carry their own safety profile. High doses of estrogens can cause bone marrow suppression (aplastic anemia), which can be fatal. Additionally, they can cause signs of estrus (swollen vulva, attractiveness to male dogs) and increase the risk of stump pyometra. Regular CBC monitoring is required.

Step 4: Surgical and Interventional Options

If medical management fails entirely, advanced interventional options can be considered:

• Urethral Bulking (Collagen Injections): Endoscopic injection of bulking agents (such as bovine collagen) into the urethral submucosa. This physically narrows the urethral lumen, increasing resistance to passive urine flow. It typically provides control for 6 to 18 months, after which the procedure can be repeated.
• Artificial Urethral Sphincter (AUS): Surgical implantation of a silicone cuff around the proximal urethra, connected to a subcutaneous port. The veterinarian can inject saline into the port to inflate the cuff, physically closing the urethra. The cuff pressure is adjusted over time to balance continence with the dog's ability to void.

---

Accidental Overdose and Ingestion Triage

Like carprofen, Proin chewable tablets are highly flavored and pose a significant risk of accidental ingestion. Accidental exposure accounted for 317 reports in the database, with overdose adding 233.

Toxicology of PPA Ingestion

An overdose of PPA results in an acute, severe sympathomimetic crisis. The clinical signs are a direct extension of the drug's stimulatory effects on the cardiovascular and central nervous systems:

• Mild Overdose (2-5× therapeutic dose): Panting, pacing, mild agitation, pupillary dilation (mydriasis), and mild hypertension.
• Moderate Overdose (5-10× therapeutic dose): Tachycardia or reflex bradycardia, moderate to severe hypertension, muscle tremors, piloerection (hair standing on end), and vocalization.
• Severe Overdose (>10× therapeutic dose): Severe hypertension (systolic BP >200–220 mmHg), cardiac arrhythmias, seizures, hyperthermia (caused by constant muscle activity), collapse, and potential death due to intracranial hemorrhage or cardiac arrest.

Emergency Triage and Treatment

If a dog ingests an overdose of Proin:

1. Seek Immediate Veterinary Care: PPA is rapidly absorbed from the gastrointestinal tract. Immediate decontamination is critical.
2. Induction of Vomiting: If the ingestion occurred within 1 hour and the dog is completely alert, vomiting should be induced (using 3% hydrogen peroxide as instructed by a veterinarian). Do not induce vomiting if the dog is showing signs of agitation, tremors, or weakness.
3. Activated Charcoal: Administer activated charcoal to prevent systemic absorption of the remaining drug.
4. Hospitalization and Monitoring: The dog must be hospitalized for 24 to 48 hours for continuous cardiovascular monitoring.
5. Pharmacological Intervention:
   • Hypertension: Treated with alpha-1 antagonists such as acepromazine (which provides vasodilatory effects and mild sedation) or nitroprusside in severe, emergent cases.
   • Tachycardia: Treated with beta-blockers such as esmolol or propranolol.
   • Agitation and Tremors: Managed with sedatives. Phenothiazines (like acepromazine) are preferred over benzodiazepines (like diazepam), as benzodiazepines can sometimes worsen excitement in sympathomimetic overdoses.

---

Frequently Asked Questions

Is Proin safe for dogs with heart disease or high blood pressure?

Generally, no. Proin is a sympathomimetic drug that causes vasoconstriction and increases blood pressure. It increases the workload on the heart and can worsen pre-existing hypertension or cardiac arrhythmias. Estrogen-based alternatives (Incurin/DES) are typically preferred for these patients.

Can I split or crush Proin ER tablets?

No. Proin ER tablets must never be split, crushed, or chewed. The tablet relies on an intact matrix to release the medication slowly over 24 hours. Breaking the tablet releases the entire dose at once, which can cause severe, acute high blood pressure.

How long does Proin take to work for incontinence?

Proin typically begins to work within 24 to 72 hours of starting treatment. Immediate-release PPA has a rapid onset of action. If the dog is still leaking after 7 days on the starting dose, contact your veterinarian to discuss dose titration.

Why does Proin stop working for some dogs?

Dogs can develop tolerance (tachyphylaxis) to sympathomimetic drugs over time as alpha-adrenergic receptors downregulate. Additionally, the underlying USMI can progress as the dog ages, or the dog may develop a secondary urinary tract infection (UTI).

Is Proin approved outside the United States?

Proin is the FDA-approved formulation of PPA in the US. In other countries, such as Canada and the UK, a liquid formulation of PPA sold under the brand name Propalin is commonly approved and used.

---

Sources

1. DailyMed / FDA National Library of Medicine: Proin ER (phenylpropanolamine hydrochloride) Extended-Release Tablets Label (NADA 141-517). Retrieved from: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6096f709-fa5a-45e1-9767-2f159f882520
2. FDA Center for Veterinary Medicine: Freedom of Information (FOI) Summary, NADA 141-517 (Approval Date: March 29, 2019); and FOI Summary, NADA 141-324 (Proin Chewable Tablets, Approval Date: August 4, 2011). Retrieved from: https://www.prnpharmacal.com/wp-content/uploads/2021/02/PROIN-ER-FOI.pdf and https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/881
3. Office of the Federal Register / Food and Drug Administration: Phenylpropanolamine-Containing Drug Products for OTC Human Use; Tentative Final Monograph (December 22, 2005). Retrieved from: https://www.federalregister.gov/documents/2005/12/22/E5-7646/phenylpropanolamine-containing-drug-products-for-over-the-counter-human-use-tentative-final
4. Today's Veterinary Practice: Phenylpropanolamine for Urinary Incontinence (Pharmacology Brief). Retrieved from: https://todaysveterinarypractice.com/pharmacology/phenylpropanolamine-for-urinary-incontinence
5. FDA Center for Veterinary Medicine / openFDA: Animal & Veterinary Event API Dataset. Retrieved from: https://api.fda.gov/animalandveterinary/event.json